Abstract: A drug delivery system for sustained delivery of bioactive agents, the system includes a matrix including nanofibrillated cellulose derived from plant based material and at least one bioactive agent, and at least one support selected from synthetic polymers, bio compounds and natural polymers. Also, methods for the manufacture of the system and methods of using it.

Abstract: The present invention relates to transdermal devices comprising prodrugs of anti-pyretic, analgesic, or anti-inflammatory molecules, methods of making such devices, and methods of use thereof for treating, preventing, minimizing, and/or diminishing fever or pain.

Abstract: The present disclosure relates to leave-on hair styling compositions, and to methods for styling hair using the compositions. The leave-on hair styling compositions include: (a) pullulan; (b) one or more cellulose ethers; (c) one or more water-soluble solvents; and (d) water. The leave-on hair styling compositions are unique in that they impart durable styling or shaping benefits, volume and fullness, smoothness, shine, texture, control fizziness, and provide overnight style, without the need for silicones and/or synthetic film forming polymers.

Abstract: A process for preparing a coagglomerate of crystalline mannitol and of starch includes spray-drying or granulating a mixture of a “solution” of mannitol and of starch, the starch being suspended in the mannitol solution. The coagglomerate has a laser volume mean diameter D4,3 between 60 and 500 ?m, and a mannitol/starch ratio is between 99.5/0.5 and 50/50. The coagglomerate, when mixed with 1.2% of magnesium stearate and formed into a cylindrical tablet with convex faces, a diameter of 13 mm, a thickness of 6 mm, and a weight of 0.734 g, has a crushing strength greater than 120 N. 100 g of said coagglomerate has a flow of between 3 and 15 seconds, measured according to European Pharmacopoeia 5.0, volume 1, 01/2005: 20916, section 2.9.1.6.

Abstract: The present invention relates to microparticles containing finasteride, as microparticles containing finasteride and a biodegradable polymer, in a form in which the microparticles have a shape in which the finasteride drug is uniformly distributed in spherical biodegradable polymer particles, and the microparticles have an average particle diameter of 20 to 70 ?m.

Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.

Abstract: A cell-free combination for use in the controlled, especially decelerated or retarded, release of active ingredient and/or in the production of a formulation in hydrogel form, especially depot formulation in hydrogel form, and/or as a formulation in hydrogel form, especially depot formulation in hydrogel form, and/or for the coating of a medical product, especially implant, preferably with a formulation in hydrogel form, especially depot formulation in hydrogel form, wherein the cell-free combination comprises a first component and a second component, the first component comprising crosslinkable albumin and the second component comprising a crosslinking agent for the albumin. Additionally, a hydrogel-forming material or hydrogel, to a kit or multicomponent system, to a medical product or a pharmaceutical formulation, to a discharge device, and to uses of the cell-free combination and of the hydrogel-forming material or hydrogel.

Abstract: The present invention relates to a pharmaceutical composition for intravascular delivery of a therapeutic agent, such as paclitaxel, rapamycin, or an analog thereof. The composition includes the therapeutic agent and a biocompatible solvent, such as glycofurol. The composition can aid tissue penetration by the therapeutic agent. A catheter assembly that protects the pharmaceutical composition from the surroundings can be used for its intravascular delivery.

Abstract: Embodiments described herein are directed to novel pharmaceutical compositions comprising a plurality of microgranules comprising nitroimidazole compounds, and uses of these pharmaceutical compositions in the treatment of bacterial vaginosis.

Abstract: The present invention provides methods for the treatment of urea cycle disorders and Maple Syrup Urine Disease.

Abstract: A method of reducing oxidative damage of skin is described. The method can include applying to oxidant damaged skin a topical composition that includes encapsulated resveratrol, oligopeptide-1, and niacinamide, wherein the combination of encapsulated resveratrol, oligopeptide-1, and niacinamide reduces oxidative damage in the skin, and wherein the oligopeptide-1 comprises the sequence of caprooyl-Gly-His-Lys-Lys.

Abstract: Methods, compositions, and devices for transdermally administering an active agent such as memantine are provided.

Abstract: Compositions comprising clay minerals and methods for their use in promoting hemostasis are provided. The compositions comprise clay minerals such as bentonite, and facilitate blood clotting when applied to a hemorrhaging wound. Electrospun or electrosprayed materials (e.g. bandages, micron beads, etc.) which include clay minerals, and methods for the treatment of acute hemorrhage, are also provided.

Abstract: The present disclosure provides oral, chewable dosage forms that are suitable for delivery of one or more active ingredients to a consumer, particularly a human individual. The dosage forms can be configured as multicomponent compositions formed of a first component including a gummy composition, at least one further component including a composition that is different from the gummy composition, and an active ingredient. The gummy composition and the second composition can be co-deposited to form multicomponent dosage forms wherein a gummy shell at least partially surrounds a core that is solid or liquid at standard temperature.

Abstract: A composition for mitigating, inhibiting, ameliorating and/or eliminating phytoplankton growth in a waterbody, the composition comprising an active ingredient at concentration of 80.0-99.5% (w/w) of the composition and a coating material at concentration of 0.5-20% (w/w) of the composition; wherein the critical surface tension of the composition is between 15-60 dyn/cm and wherein the relative density of the composition, prior to being submerged in water, is above 1 g/cm3.

Abstract: The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.

Abstract: A solid dosage form for injection and a method of making said dosage form wherein the dosage form has a moisture content of 5% (w/w) or less. The solid dosage form comprises a dried matrix including a first excipient and 0.01 to 50% (w/w) or more than 50% and up to 80% (w/w) of a therapeutic peptide; and one or more additional excipients and at least 5% (w/w) of CMC, based on the total weight of the solid dosage form, wherein the dosage form has a width of 0.5 mm to 2 mm.

Abstract: The present invention relates to complex particles using methylene blue for treating a skin disease caused by Propionibacterium acnes or Staphylococcus aureus and a composition for treatment including the complex particles. The complex particles in the present invention can be used as a photosensitizer for a photodynamic therapy and complex particles having a micelle form in which hydrophilic methylene blue and two hydrophobic organic acids are combined, and as a result, pore penetration is easy and an occlusion time can be significantly reduced to 30 minutes as compared with conventional phototherapy requiring an occlusion time of 1 hour to 3 hours.

Abstract: A composition for mitigating, inhibiting, ameliorating and/or eliminating phytoplankton growth in a waterbody, the composition comprising an active ingredient at concentration of 80.0-99.5% (w/w) of the composition and a coating material at concentration of 0.5-20% (w/w) of the composition; wherein the critical surface tension of the composition is between 15-60 dyn/cm and wherein the relative density of the composition, prior to being submerged in water, is above 1 g/cm3.

Abstract: Disclosed are a green environmental facial cleansing tissue with a natural plant origin and its preparation method, particularly a green facial cleansing tissue with a makeup removal function and a natural plant origin formula and its preparation method. The formula of the facial cleansing tissue consists of natural plants, honey extracts, etc., and the facial cleansing tissue is capable of avoiding skin irritation, providing a convenient and safe use, and the facial cleansing tissue is naturally decomposable and environmentally friendly.